X4 Pharmaceuticals, Inc. XFOR
3.01
0.01
0.33%
as of 25 Sep
- Market cap
- $297.4M
- P/E
- 0.0×
Follow XFOR
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (113.08%) | (104.21%) | (75.99%) | (156.87%) |
+8 more TTM periods Free account |
|
| (50.32%) | (49.82%) | (36.25%) | (55.66%) | ||
ROIC |
(226.62%) | (543.03%) | (566.65%) | (399.12%) | |
Return on Tangible Assets |
(45.16%) | (45.67%) | (33.56%) | (86.83%) | |
Average Days of Receivables |
47.15 | 45.07 | 5.96 | 17.25 | |
Free Cash Flow per Share |
(0.70) | (0.74) | (2.10) | (2.45) | |
Free Cash Flow |
(88.74) | (92.85) | (88.62) | (106.09) | |
Capital Expenditures |
(5.00) | — | (3.00) | (3.00) | |
Piotroski F-Score |
4.00 | 3.00 | 3.00 | 0.00 | |
| Other line items | |||||
Cash ROIC |
(19.02%) | (19.40%) | (16.61%) | (39.67%) | |
Accounts Receivable Turnover |
8.10 | 7.88 | 30.76 | 25.37 | |
Accounts Payable Turnover |
0.50 | 0.20 | 0.80 | 0.84 | |
Inventory Turnover |
0.68 | 0.42 | 1.58 | 1.75 | |
Average Days of Payables |
490.07 | 1,129.74 | 361.13 | 323.85 | |
Days of Inventory on Hand |
685.40 | 1,032.64 | 283.97 | 261.49 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
418.92% | 772.80% | 207.11% | 223.39% | |
Selling, General and Administrative Expense of Revenue |
217.30% | 393.40% | 123.93% | 150.91% | |
Share Based Compensation of Revenue |
53.83% | 68.69% | 12.24% | 12.49% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 0.93 | 1.08 | 1.08 | |
Depreciation/Fixed assets |
15.01 | 7.01 | 7.02 | 6.09 | |
Capex/Depreciation |
(3.00) | 0.00 | (2.35) | (2.26) | |
Revenue per Share |
0.13 | 0.07 | 0.83 | 0.79 | |
Operating CF per Share |
(0.66) | (0.74) | (2.02) | (2.38) | |
Capex per Share |
(0.04) | 0.00 | (0.07) | (0.07) | |
Capex to Sales |
0.32 | 0.00 | 0.09 | 0.09 | |
Net Profit Margin |
(568.80%) | (1,106.30%) | (225.55%) | (279.86%) |
Columns are period end dates